# Xuezhi Hao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xuezhi-hao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,665 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 24 |
| i10-index | 56 |
| Last Known Institution | Chinese Academy of Medical Sciences & Peking Union Medical College |
| OpenAlex ID | https://openalex.org/A5048001385 |
| ORCID iD | 0000-0002-1285-5562 |
| Works | 192 |

## Researcher papers

- [Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes](https://scholariq.org/papers/acquired-resistance-to-osimertinib-in-patients-with-non-small-cell-lung-cancer/)
- [miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer](https://scholariq.org/papers/mir-130a-regulates-macrophage-polarization-and-is-associated-with-non-small-cell/)
- [Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of <scp>358</scp> patients](https://scholariq.org/papers/survival-and-pretreatment-prognostic-factors-for-extensive-stage-small-cell-lung/)
- [Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma](https://scholariq.org/papers/comprehensive-profiling-of-gene-copy-number-alterations-predicts-patient/)
- [Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-amrubicin-cisplatin-versus-etoposide-cisplatin-as/)
- [Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study](https://scholariq.org/papers/intracranial-efficacy-of-alectinib-in-alk-positive-nsclc-patients-with-cns/)
- [Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer](https://scholariq.org/papers/circular-rna-profiling-identified-as-a-biomarker-for-predicting-the-efficacy-of/)
- [Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib](https://scholariq.org/papers/clinical-modality-of-resistance-and-subsequent-management-of-patients-with/)
- [Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma](https://scholariq.org/papers/comprehensive-analysis-of-treatment-modes-and-clinical-outcomes-of-small-cell/)
- [First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for <i>HER2</i> -altered NSCLC: a retrospective real-world POLISH study](https://scholariq.org/papers/first-line-immunotherapy-or-angiogenesis-inhibitor-plus-chemotherapy-for-i-her2/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Chinese Academy of Medical Sciences & Peking Union Medical College](https://scholariq.org/institutions/chinese-academy-of-medical-sciences-and-peking-union-medical-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.